Cimetidine protects against stress-induced gastric injury augmented by mucosal barrier breakers.
An experimental rat model utilizing cold-restraint stress was employed to test the ability of an H2-receptor antagonist, cimetidine, to control gastric mucosal injury associated with stress augmented by the gastric mucosal barrier breakers, aspirin and taurocholate. Both aspirin and taurocholate, when combined with stress, caused a significant increase in gastric mucosal injury over that seen in animals receiving either stress alone or only gastric mucosal barrier breakers without stress. Pretreatment with cimetidine caused a significant reduction in gastric mucosal injury in stressed animals receiving gastric mucosal barrier breakers. This reduction was to the level of lesions seen in nonstressed animals.
D000818:Animals; D001241:Aspirin / Q000009:adverse effects; D002927:Cimetidine / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006146:Guanidines / Q000627:therapeutic use*; D051381:Rats; D013276:Stomach Ulcer / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D013312:Stress, Physiological / Q000150:complications*; D013656:Taurocholic Acid / Q000009:adverse effects
D006146:Guanidines; D013656:Taurocholic Acid; D002927:Cimetidine; D001241:Aspirin